Assertio Holdings Acquired by Zydus Lifesciences; Delisted from Nasdaq
Summary
Assertio Holdings has finalized its acquisition by Zydus Lifesciences for $23.50 per share in cash, leading to its delisting from Nasdaq and a change in control for convertible noteholders.
Key Events
-
Merger Completion and Delisting
Assertio Holdings, Inc. has been acquired by Zydus Worldwide DMCC for $23.50 per share in cash, and its common stock has been delisted from the Nasdaq Stock Exchange, effective June 16, 2026.
-
Convertible Notes Impact
The merger constitutes a 'Fundamental Change' and 'Make-Whole Fundamental Change' for the 6.50% Convertible Senior Notes due 2027. Noteholders can demand repurchase at 100% principal plus accrued interest, or convert into cash at approximately $382.58 per $1,000 principal amount.
-
Board and Officer Changes
The previous board of directors and officers have resigned, with new directors Ravi Yadavar and Punit Patel, from the acquirer, taking their places as Assertio becomes a wholly-owned subsidiary.
-
Corporate Governance Amendments
The company's certificate of incorporation and bylaws have been amended and restated to reflect its new corporate structure under Zydus Lifesciences.
Analysis
Assertio Holdings, Inc. has completed its acquisition by Zydus Worldwide DMCC, a subsidiary of Zydus Lifesciences Ltd., for $23.50 per share in cash. This definitive event marks the end of Assertio's independent public trading, with its common stock now delisted from the Nasdaq Stock Exchange. The merger also triggers a 'Fundamental Change' and 'Make-Whole Fundamental Change' for holders of Assertio's 6.50% Convertible Senior Notes due 2027, granting them the right to require repurchase at par plus accrued interest, or convert into cash at approximately $382.58 per $1,000 principal amount. The company's board and officers have resigned, replaced by Zydus representatives, and the corporate charter and bylaws have been amended to reflect its new status as a wholly-owned subsidiary.
At the time of this filing, ASRT was trading at $23.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $151.9M. The 52-week trading range was $8.61 to $23.50. This filing was assessed with neutral market sentiment and an importance score of 10 out of 10.